braftovi

Generic: encorafenib

braftovi: developed by 1 company · 1 FDA decision. Updated within the last hour.

Development Pipeline (1)

CompanyPhase
ARRAY BIOPHARMA INC (ARRY)Approved

FDA Decisions

Approval1 INDICATIONS AND USAGE BRAFTOVI is a kinase inhibitor indicated: Melanoma • in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-authorized test. ( 1.1 , 2.1 ) Colorectal Cancer (CRC) • in combination with cetuximab and fluorouracil-based chemotherapy, for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA‑authorize(ARRY)

Frequently asked questions

Who is developing braftovi?

braftovi is being developed by ARRAY BIOPHARMA INC.

What is braftovi's latest FDA decision?

The most recent tracked FDA decision for braftovi is Approval for 1 INDICATIONS AND USAGE BRAFTOVI is a kinase inhibitor indicated: Melanoma • in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-authorized test. ( 1.1 , 2.1 ) Colorectal Cancer (CRC) • in combination with cetuximab and fluorouracil-based chemotherapy, for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA‑authorize, dated June 27, 2018.

Get deeper analysis on braftovi

Full trial data, mechanism of action, competitive landscape, and AI-powered insights.

Start Free Analysis
    braftovi — Drug Pipeline, Trials & FDA Status | BioSniper